Catalio Capital Management was created by George Petrocheilos and Dr. Jacob Vogelstein to invest in breakthrough biomedical technology companies created or referred by Catalio Capital Management, an elite group of world-renowned, serial scientist-entrepreneurs.
Location: United States, New York
Employees: 51-200
Founded date: 2020
Investment Stage: Series A; Series B
Portfolio 79
| Date | Name | Website | Total Raised | Location |
| 10.10.2024 | Orasis | orasis-pharma.com | $43M | - |
| 16.09.2024 | Imperative... | imperativecare.com | $495M | United Sta... |
| 16.09.2024 | Superlumin... | superluminalrx.com | $120M | - |
| 16.09.2024 | Audicus | audicus.com | - | United Sta... |
| 16.09.2024 | Tessera Th... | tesseratherapeutics.com | $530M | United Sta... |
| 16.09.2024 | Protara | protaratx.com | - | United Sta... |
| 16.09.2024 | Clasp Ther... | clasptx.com | - | - |
| 19.03.2024 | FogPharma | fogpharma.com | $496M | United Sta... |
| 18.03.2024 | Roshal Ima... | roshalimaging.com | - | United Sta... |
| 19.02.2024 | AVAVA | avavaskin.com | $35M | - |
Show more
Persons 101
| Date | First Name | Last Name | Title | Location | |||
| - | Raju | Kucherlapa... | Venture Pa... | linkedin.c... | - | - | - |
| - | Brian | Brennan | General Co... | linkedin.c... | - | b******n@c... | - |
| - | John | Henry Iuck... | General Pa... | linkedin.c... | - | j*****r@ca... | - |
| - | Freda | Lewis-Hall... | Venture Pa... | linkedin.c... | - | - | - |
| - | Michael | Cheaney, C... | Vice Presi... | linkedin.c... | - | m******y@c... | - |
| - | Henry | Brem, M.D. | Venture Pa... | linkedin.c... | - | - | - |
| - | James | Schenck | Analyst | linkedin.c... | - | j******k@c... | - |
| - | Tom | V. Brooks | Partner | linkedin.c... | - | t*****s@ca... | - |
| - | Madonna | Davidson | Head of In... | linkedin.c... | - | m*******n@... | - |
| - | David | Stonko, M.... | Clinical A... | linkedin.c... | - | d*****o@ca... | - |
Show more
Mentions in press and media 24
| Date | Title | Description |
| 13.08.2024 | Australian biotech incubator Proto Axiom announces $20M Series B first close | $20M unlocked for opportunities in Australian biotech innovation, valuing Proto Axiom at $90M SYDNEY, Aug. 13, 2024 /PRNewswire/ -- Proto Axiom, the Australian biomedical technology incubator has today announced a $20 million first close of... |
| 12.03.2024 | Texas-based 'hop-on' jet service offers exclusive eclipse flight flown by NASA pilot | With Texas set to be the prime location for the Great North American Solar Eclipse, airlines are lining up to offer the best vantage point and that includes JSX: The private carrier is offering a once-in-a-lifetime in-flight experience to 1... |
| 12.03.2024 | Houston health tech company announces $10M in fresh funding to bolster customer care | Roshal Health, a Katy-based provider of ultrasound and echocardiogram services for health care facilities, has secured $10 million in structured equity financing. New York City-based investment firm Catalio Capital Management led the financ... |
| 29.08.2023 | TapestryHealth Secures $25M Credit Investment | What You Should Know: TapestryHealth, a multi-specialty healthcare company, announced a $25M credit investment from Catalio Capital Management, a leading multi-strategy investment firm focused on healthcare and life sciences. The senior sec... |
| 17.05.2022 | Character Biosciences Raises $18M to Expand Precision Medicine Platform for Diseases of Aging | What You Should Know: – Character Biosciences (“Character”), a precision medicine platform for diseases of aging raises $18M in a new funding round led by Innovation Endeavors, alongside leading life sciences investors Section 32 and Catali... |
| 04.05.2022 | Catalio reloads with $381M after financing Octant, Pheast | Catalio Capital Management, the life sciences investment firm behind recent funding rounds from Pheast Therapeutics, Octant and more, has reloaded with another $381 million—its largest fund to date to support breakthrough biotech companies.... |
| 04.05.2022 | Catalio snags over $381M for Fund III | Catalio Capital Management has closed its third life sciences fund with more than $381 million in capital commitments, surpassing a target of $300 million. The fund will be used to back biomedical tech companies at all stages of growth. Ope... |
| 03.05.2022 | Catalio Capital Management closes $381M venture fund | Biomedical industry-focused investment firm Catalio Capital Management today announced the close of a venture fund that its cofounder says will help it grow Baltimore’s own life sciences industry. The Catalio Nexus Fund III is worth $381 mi... |
| 03.05.2022 | This private equity firm is sharing returns with portfolio company employees | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. When a record number of people are quitting their jobs, it may help to give employees a stake in ... |
| 03.05.2022 | Catalio Capital Management Closes $381M Third Life Sciences Fund | Catalio Capital Management, LP, a NYC-based multi-strategy life sciences investment firm, closed its third venture fund, Catalio Nexus Fund III, at more than $381m. The fund received backing from current investors and a number of new, globa... |
Show more